Fortress Biotech (NASDAQ:FBIOP – Get Free Report) will likely be announcing its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $26.17 million for the quarter.
Fortress Biotech Stock Down 1.5%
Shares of FBIOP stock opened at $13.10 on Tuesday. Fortress Biotech has a 12-month low of $4.72 and a 12-month high of $14.64. The business’s fifty day simple moving average is $12.68 and its 200-day simple moving average is $9.64.
About Fortress Biotech
Fortress Biotech, Inc (NASDAQ: FBIOP) is a biopharmaceutical company that acquires, develops and commercializes innovative therapeutics for the treatment of patients with serious diseases. Operating as a biotech accelerator, Fortress Biotech partners with experienced management teams to advance products from early-stage discovery through regulatory approval and commercial launch. Its diversified portfolio spans multiple therapeutic areas, including oncology, rare diseases, dermatology, ophthalmology and neuromuscular disorders.
The company’s business model centers on establishing and funding product-centric subsidiary companies, each focused on a specific drug candidate or therapy.
Featured Stories
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
